Kilitch Drugs (India) Limited (IN:KILITCH)
:KILITCH
Want to see IN:KILITCH full AI Analyst Report?
KILITCH Stock Chart & Stats
₹355.60
₹0.95(0.27%)
At close: 4:00 PM EST
₹355.60
₹0.95(0.27%)
Day’s Range― - ―
52-Week Range₹121.10 - ₹245.00
Previous CloseN/A
Volume65.63K
Average Volume (3M)2.19K
Market Cap
₹5.36B
Enterprise Value₹5.90B
Total Cash (Recent Filing)₹870.13M
Total Debt (Recent Filing)₹836.13M
Price to Earnings (P/E)34.5
Beta0.78
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.39
Shares Outstanding34,961,563
10 Day Avg. Volume2,304
30 Day Avg. Volume2,185
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.86
Price to Sales (P/S)2.92
P/FCF Ratio-19.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.5
Revenue Forecast (FY)₹2.64B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~13.8% revenue growth indicates durable end-market demand and successful commercial execution. Over 2–6 months this supports scale advantages, better absorption of fixed costs, and greater reinvestment capacity into R&D, exports or capacity expansion, underpinning medium-term topline resilience.
Profitability ImprovementImproving net profit and healthy gross margins point to effective pricing and cost control. This enhances sustainable earnings power, funds strategic initiatives without relying solely on external financing, and increases ability to withstand pricing or input-cost pressure over a multi-quarter horizon.
Stable Balance SheetA strong equity base with moderate leverage provides financial flexibility for investing in growth or absorbing downturns. This stability lowers refinancing risk, enables measured capital allocation (capex or selective M&A), and supports sustained operations through industry cycles.
Bears Say
Weak Cash ConversionDeteriorating free cash flow and suboptimal cash conversion of earnings reduce internal funding for growth, dividends, or deleveraging. Over months this constrains strategic flexibility, increases reliance on external financing for capex, and raises vulnerability if margins or sales soften.
Higher Capex BurdenElevated capital expenditure, while potentially growth-oriented, is pressuring cash flows and free cash flow generation. Persisting capex requirements over 2–6 months could suppress near-term cash returns and necessitate higher working capital or borrowing, limiting optionality for other priorities.
Operational Efficiency LimitsAlthough profitable, suboptimal EBIT/EBITDA margins indicate limited operational leverage. Without productivity gains or cost structure improvements, revenue growth may not fully translate into stronger cash flows or returns, constraining competitiveness and long-term margin expansion.
Kilitch Drugs (India) Limited News
KILITCH FAQ
What was Kilitch Drugs (India) Limited’s price range in the past 12 months?
Kilitch Drugs (India) Limited lowest stock price was ₹121.10 and its highest was ₹245.00 in the past 12 months.
What is Kilitch Drugs (India) Limited’s market cap?
Kilitch Drugs (India) Limited’s market cap is ₹5.36B.
When is Kilitch Drugs (India) Limited’s upcoming earnings report date?
Kilitch Drugs (India) Limited’s upcoming earnings report date is May 27, 2026 which is in 22 days.
How were Kilitch Drugs (India) Limited’s earnings last quarter?
Kilitch Drugs (India) Limited released its earnings results on Feb 11, 2026. The company reported ₹1.268 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.268.
Is Kilitch Drugs (India) Limited overvalued?
According to Wall Street analysts Kilitch Drugs (India) Limited’s price is currently Overvalued.
Does Kilitch Drugs (India) Limited pay dividends?
Kilitch Drugs (India) Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Kilitch Drugs (India) Limited dividends here
What is Kilitch Drugs (India) Limited’s EPS estimate?
Kilitch Drugs (India) Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kilitch Drugs (India) Limited have?
Kilitch Drugs (India) Limited has 34,961,563 shares outstanding.
What happened to Kilitch Drugs (India) Limited’s price movement after its last earnings report?
Kilitch Drugs (India) Limited reported an EPS of ₹1.268 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.637%.
Which hedge fund is a major shareholder of Kilitch Drugs (India) Limited?
Currently, no hedge funds are holding shares in IN:KILITCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Technical Analysis
Albert David Ltd
―
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Valiant Laboratories Ltd.
―
Zim Laboratories Ltd.
―